07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Afrezza, partnered

Having signed on as the commercial partner for MannKind Corp. 's Afrezza inhaled insulin, Sanofi is clearly betting it can succeed where Exubera inhaled insulin from Pfizer Inc. and Nektar Therapeutics failed. To make the...
07:00 , Apr 28, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick Christopher James New Market outperform -4% $8.01 James initiated coverage with a $15 target. He expects...
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks Christopher James joined boutique investment bank Brinson Patrick Securities Corp. as a senior analyst focused on life science companies. Two managing directors have left Brinson: Vernon Bernardino, who had been a senior research...
07:00 , May 20, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/17 cls Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Downgrade Neutral (from buy) -2% CHF58.80 Renterghem said Actelion's share price is almost in line...
07:00 , Sep 10, 2012 |  BioCentury  |  Finance

Banker tracks

Banker tracks Vernon Bernardino joined boutique investment bank Brinson Patrick Securities Corp. as a senior research analyst focused on life sciences companies. Bernardino, who founded strategic advisory group Oceros Advisors, previously held analyst positions at...
07:00 , Jul 23, 2012 |  BioCentury  |  Finance

Banker tracks

Banker tracks Kevin Tyler joined boutique investment bank Brinson Patrick Securities Corp. as managing director of healthcare investment banking. He was an SVP responsible for financing and advisory assignments for healthcare companies at Global Hunter...
01:19 , May 25, 2012 |  BC Extra  |  Financial News

Life sciences visits the ATM

U.S. life sciences companies raised a record $90 million through at-the-market (ATM) offerings in 1Q12, according to data from ATM specialist Brinson Patrick Securities Corp. That's a 36% increase over 1Q11, which previously had the...
07:00 , May 7, 2012 |  BioCentury  |  Finance

Into the darkness

The placement of large blocks of shares with long-term institutional investors may seem unattainable for many small cap biotechs. But Liquidnet Holdings Inc. , a so-called "dark pool" trading platform, is now targeting these companies...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

Venture tracks

Venture tracks David Wetherell and Douglas Lind joined the Burrill & Co. venture capital group as managing directors. Joshua Zelig joined as a director. Wetherell was founder of GBP Capital. Lind was a managing director...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...